Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01064622 · ClinicalTrials.gov registry record · Phase 2
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 118
- Enrollment target
NCT01064622: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT01064622 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 118 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01064622, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 118 participants
- Enrollment target
Study Summary
This randomized phase I/II trial studies gemcitabine hydrochloride and vismodegib to see how well they work compared with gemcitabine hydrochloride alone in treating patients with recurrent or metastatic pancreatic cancer. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vismodegib may slow the growth of tumor cells. It is not yet known whether giving gemcitabine hydrochloride together with vismodegib is more effective than gemcitabine hydrochloride alone in treating patients with pancreatic cancer.
Interventions
- DRUG Vismodegib
- DRUG Gemcitabine Hydrochloride
- OTHER Hydrocortisone/Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2009-09-03 |
| Est. Completion | 2013-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01064622
The ClinicalTrials.gov registry entry for NCT01064622 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 118 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Vismodegib is the first listed.
NCT01064622 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01064622 about?
NCT01064622 is a clinical study titled "Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer". This randomized phase I/II trial studies gemcitabine hydrochloride and vismodegib to see how well they work compared with gemcitabine hydrochloride alone in treating patients with recurrent or metastatic pancreatic cancer. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in differ...
What is the current status of trial NCT01064622?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 118 participants. The study started on 2009-09-03. Estimated completion is 2013-01-31.
What interventions are being tested in trial NCT01064622?
The interventions under investigation include: Vismodegib (DRUG), Gemcitabine Hydrochloride (DRUG), Hydrocortisone/Placebo (OTHER).
Who is sponsoring clinical trial NCT01064622?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.